Group Santoro publishes major study on predictive marker of prostate cancer recurrence in Nature Genetics
A yardstick to measure the malignancy of prostate cancer
A protein that influences the epigenetic characteristics of tumor cells is directly linked to the grade of malignancy of prostate cancer. This key discovery has been made by a team of scientists from the University of Zurich, German Cancer Research Center (DKFZ), Hamburg-Eppendorf University Hospital, Heidelberg University, and other institutes in a study of 7,700 samples of tumor tissue. The detection of this biomarker may serve as an indicator of the likelihood that the disease may take an aggressive course, and may thus be helpful in choosing an appropriate treatment.
When cancer is diagnosed, the grade of its malignancy is a central concern for both patients and their physicians. This value is used to determine how intensively and how radically the cancer must be treated. Particularly in the case of prostate cancer, the disease can take widely varying courses in different patients. Therefore, cancer researchers have been looking for measurable, reliable biomarkers that give clues about the aggressiveness of a tumor in order to choose an appropriate therapy.
In many types of cancer, alterations in a tumor's genetic material indicate how dangerous the cancer is. Prostate cancer, however, exhibits far fewer of these mutations than other cancer types. "We have therefore suspected that prostate cancer is driven primarily by alterations in epigenetic characteristics, that is, chemical changes in the genetic material that do not affect the sequence of DNA building blocks," says Prof. Christoph Plass from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), who is one of the project leaders in the current publication.
For a long time, the means by which epigenetic patterns in the DNA of cancer cells undergo changes have remained a mystery. Scientists have discovered specific cellular proteins that can have a major influence on such patterns. A network of researchers from the University of Zurich, German Cancer Research Center (DKFZ), Hamburg-Eppendorf University Hospital, Heidelberg University, and other institutes have been searching for regulatory proteins that change the epigenetic characteristics of prostate cancer cells and may thus have an impact on the course of the disease.
In a first step, the scientists searched databases containing molecular information on a large number of prostate cancer cases. Using these data, they investigated whether a particular, known epigenetic regulatory protein is expressed in tumor cells at significantly higher or lower levels than in healthy cells from the same patient.
The researchers found the most obvious differences in the expression of a protein called BAZ2A. "The normal known function of this protein is to suppress factories that produce cellular proteins and thus affect the viability of cells," says Dr. Raffaella Santoro from the University of Zurich, who is the other project leader of this work and expert of BAZ2A protein. "But when we turned off BAZ2A in the cell lines of metastasizing prostate cancer, their growth was paradoxically slowed." Further studies showed that higher levels of BAZ2A increased specific malignant properties of prostate cancer cells, including their mobility and capacity to invade surrounding tissue. A detailed molecular analysis of prostate cancer cells showed that the overproduction of BAZ2A led to alterations in epigenetic patterns which then inhibited the activity of a number of cancer-suppressing genes.
The scientists therefore suspected that the overexpression of BAZ2A might have a direct impact on the malignancy of prostate cancer and thus serve as a predictor for the course of the disease. The team investigated this hypothesis using nearly 7,700 tissue samples obtained from prostate cancer patients. They discovered that the higher the BAZ2A levels in the tissue were, the more advanced the tumor was at the time of diagnosis, the more frequently it had already spread and formed metastases, and the higher patients' PSA levels were.
"BAZ2A seems to have a direct influence on the aggressiveness of prostate cancer," Plass says. "This suggests that levels of BAZ2A expression may serve as a valuable predictor of disease progression. Of course, this still needs to be clinically confirmed. Particularly in patients whose other clinical results indicate a medium risk, BAZ2A expression may provide important clues for the actual chances of recurrence. This would help physicians and patients choose the most promising treatment.
This study is a cooperation between the University of Zurich, the German Cancer Research Center, the University of Heidelberg, the Martini-Klinik and Hamburg-Eppendorf University Hospital, EMBL, the National Center for Tumor Diseases (NCT) Heidelberg, the Max Planck Institute for Molecular Genetics in Berlin and the International Cancer Genome Consortium (ICGC).
Publication: Gu, L., Frommel, S.C., Oakes, C.C., Simon, R., Grupp, K., Gerig, C.Y., Bar, D., Robinson, M.D., Baer, C., Weiss, M., Gu, Z., Schapira, M., Kuner, R., Sultmann, H., Provenzano, M., Cancer, I.P.o.E.O.P., Yaspo, M.-L., Brors, B., Korbel, J., Schlomm, T., Sauter, G., Eils, R., Plass, C., and Santoro, R. (2014). BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence. Nature Genetics, advance online publication. doi: 10.1038/ng.3165
link to UZH news
For further information on the research performed in the Group of Dr. Raffaella Santoro see
link to Group Santoro
- The Dutch Research Council (NOW) awarded a 2 year Rubicon grant to Dr. Yannick Kok for his project DNA repair: wrong place, wrong time
- Award Ceremony and Lectures Dr. Ernst Th. Jucker Preis 2019/2020 for Important Contributions to Cancer Research
- The project of the MSRU “Human-Horse Interaction” was awarded the “Prize for Educational Innovations” ”from the Hans-Peter Frey Foundation
- Kaivalya Walavalkar received the prestigious EMBO postdoctoral fellowship
- Scott Finlay PhD and Salim Darwiche PhD awarded first prize for best investor pitch, presenting their marketable product for cartilage repair
- Congratulations to SNSF Prof. Dr. Matthias Altmeyer for being appointed Associate Professor
- Congratulations to Prof.em. Dr. Brigitte von Rechenberg for obtaining ORS 2020 Women’s Leadership Forum Award
- Stephanie Lüthi receives semester price 2019 from VSF
- Prof. Dr. Tuncay Baubec receives ERC Consolidator Grant
- Ramon Pfändler receives semester price from MNF
- Nina Schmolka receives SNF Ambizione Fellowship
- New paper from group M. Altmeyer online in EMBO journal
- Molecular biologist Tuncay Baubec received the renowned Georg Friedrich Götz Award
- Preisgekrönte Nachwuchsforschung
- Verlängerung SNF Förderungsprofessur von Prof. Dr. Tuncay Baubec
- Erfolgsmeldung aus dem Department of Molecular Mechanisms of Disease
- Proteinveränderungen weisen auf Krebs hin
- Mass spectrometry method provides first view of stress-induced extracellular protein modification in cells and tissues
- Tumor Therapy of the Future
- Measuring the Effects of Drugs on Cancer Cells
- Prolongation of SNSF Professorship for Prof. Dr. Matthias Altmeyer
- Raffaella Santoro received the prestigious ERC advanced grant
- Article in UZH Magazin about Matthias Altmeyer on his work "Krebszellen im Burnout"
- Successful and stimulating 3rd Joint Department Colloquium (JDC) of the DMMD
- Important Mechanism of Epigenetic Gene Regulation Identified
- UZH press release on the work of Santoro and Cinelli groups on stem cell pluripotency in Nature Cell Biology
- Professorial appointment process successfully completed
- SNF Prof. Dr. Matthias Altmeyer receives highly prestigious ERC Starting Grant
- Dr. Francisco Verdeguer new group leader at DMMD
- Prof. Dr. Raffaella Santoro elected as new EMBO member
- Dr. Sandra Frommel from the Santoro group receives Jahrespreis of the Vetsuisse Faculty
- Group van Loon publishes on the impact of ribonucleotide incorporation on DNA base excision repair in Nature Communications
- Dr. Barbara van Loon appointed to Associate Professor position at the Norwegian University for Science and Technology
- IVBMB is now Department of Molecular Mechanisms of Disease (DMMD)
- Group Hottiger publishes on identification of genome-wide chromatin ADP-riboslyation in Molecular Cell
- Group Altmeyer publishes on intracellular phase separation in Nature Communications
- IVBMB now also associated with Faculty of Science (MNF)
- Dr. Tuncay Baubec awarded SNF-professorship to be carried out at the IVBMB
- Group Santoro awarded for Cell Stem Cell Cover Page
- Dr. Matthias Altmeyer awarded SNF-professorship to be carried out at the IVBMB
- Prof. Michael O. Hottiger new acting director of IVBMB as of 1. February 2014